Fate Therapeutics
FATE
#8182
Rank
โ‚ฌ0.28 B
Marketcap
2,48ย โ‚ฌ
Share price
1.25%
Change (1 day)
153.06%
Change (1 year)

Revenue for Fate Therapeutics (FATE)

Revenue in 2026 (TTM): โ‚ฌ5.38 Million

According to Fate Therapeutics 's latest financial reports the company's current revenue (TTM ) is โ‚ฌ5.53 Million. In 2025 the company made a revenue of โ‚ฌ5.65 Million a decrease over the revenue in the year 2024 that were of โ‚ฌ13.09 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Fate Therapeutics from 2013 to 2026

Annual revenue

Year Revenue Change
2026 (TTM) โ‚ฌ5.38 M-4.74%
2025 โ‚ฌ5.65 M-56.81%
2024 โ‚ฌ13.09 M-77.21%
2023 โ‚ฌ57.47 M-35.98%
2022 โ‚ฌ89.77 M82.05%
2021 โ‚ฌ49.31 M92.96%
2020 โ‚ฌ25.55 M168.06%
2019 โ‚ฌ9.53 M130.1%
2018 โ‚ฌ4.14 M21.08%
2017 โ‚ฌ3.42 M-18.23%
2016 โ‚ฌ4.18 M88.23%
2015 โ‚ฌ2.22 M
2014 N/A-100%
2013 โ‚ฌ0.7 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Becton Dickinson
BDX
โ‚ฌ18.71 B 338,183.72%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
โ‚ฌ1.91 B 34,481.76%๐Ÿ‡บ๐Ÿ‡ธ USA
PTC Therapeutics
PTCT
โ‚ฌ0.72 B 12,995.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
โ‚ฌ2.71 B 49,019.70%๐Ÿ‡บ๐Ÿ‡ธ USA
Avidity Biosciences
RNAM
โ‚ฌ16.42 M 196.94%๐Ÿ‡บ๐Ÿ‡ธ USA